Why the study?
The study aimed to evaluate the incidence of adverse drug reactions and their relationship with morphine dose/duration or renal insufficiency in patients with end-stage HF receiving continuous morphine infusion.
What is the incidence and what are the predictors of adverse drug reactions in end-stage heart failure patients receiving continuous morphine infusion?
What is the incidence and what are the predictors of adverse drug reactions in end-stage heart failure patients receiving continuous morphine infusion?
In patients with end-stage heart failure, continuous morphine infusion causes adverse drug reactions in over a third of patients, with the risk significantly increased in those with an eGFR < 32 mL/min/1.73 m2.
No takes yet. Share an insight, caveat, or question.
Monitor closely for ADRs during morphine infusion in end-stage HF; leaves open dose and renal function relationships.
Gotou et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: